| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Z-Asp-Ome is classified as a protected amino acid derivative and an aspartic acid analogue. It does not have a specific biological receptor target. It serves as a building block in peptide synthesis and the preparation of various bioactive compounds. The orthogonal protecting groups allow for selective deprotection and functionalization, making it a versatile intermediate for constructing complex molecules, including peptides and peptidomimetics.
|
|---|---|
| ln Vitro |
Commercial ergot supplements have been made from amino acids and their derivatives. They affect the release of anabolic hormones, the availability of fuel for activity, the ability to think clearly under pressure, and the prevention of muscular damage brought on by exertion. They are regarded as advantageous synergistic food ingredients [1].
In vitro activity for Z-Asp-Ome is primarily as a peptide synthesis intermediate. Amino acid derivatives have been studied as ergogenic supplements, influencing anabolic hormone secretion and fuel availability. Z-Asp-Ome itself is not directly biologically active. Its utility is in preparing aspartic acid-containing peptides and other compounds for subsequent biological evaluation. |
| ln Vivo |
In vivo activity data for Z-Asp-Ome as a standalone compound is not applicable. It is a protected amino acid derivative used as a research intermediate. The compound is not intended for direct in vivo administration. Peptides or other compounds synthesized using this building block may be evaluated in animal models. The protecting groups are typically removed before biological testing.
|
| Enzyme Assay |
In vitro protocols for Z-Asp-Ome are primarily synthetic. It is used as an intermediate in peptide synthesis. The methyl ester can be selectively hydrolyzed under basic conditions, or the Z group can be removed by hydrogenolysis. The free acid or amine can then be used for further coupling reactions. Purity is typically ≥98%. Storage is recommended at -20°C for long-term stability.
|
| Cell Assay |
Cell-based protocols are not applicable to Z-Asp-Ome as it is a protected amino acid derivative. It is not typically used in cell culture. Biological testing would be performed on the final, deprotected compounds synthesized from this intermediate. The compound should be handled as a standard laboratory chemical.
|
| Animal Protocol |
Animal studies are not conducted with Z-Asp-Ome directly. The compound may be used as a synthetic intermediate to prepare compounds for pharmaceutical research. The methyl ester and Z protecting groups are typically removed before any biological testing. Standard synthetic chemistry protocols are used to convert this intermediate into target molecules for potential in vivo evaluation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of Z-Asp-Ome are not applicable as it is a research intermediate. The compound has a molecular weight of 281.26 g/mol, a calculated LogP of 2.11, and a melting point of 89.3°C (dec.). Storage is recommended as a powder at -20°C for long-term stability. It is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
Limited toxicological data is available for Z-Asp-Ome. The compound is for research use only. Standard safety precautions should be observed. No specific toxicity studies have been reported. It is not intended for human therapeutic use. Store as a powder at -20°C for up to 3 years or at 4°C for up to 2 years.
|
| References |
[1]. Luckose F, et al. Effects of amino acid derivatives on physical, mental, and physiological activities. Crit Rev Food Sci Nutr. 2015;55(13):1793-1144.
|
| Additional Infomation |
Z-Asp-Ome (CAS#: 4668-42-2) is also known as N-Cbz-L-aspartic acid 1-methyl ester, Z-L-aspartic acid α-methyl ester, and (3S)-4-methoxy-4-oxo-3-(phenylmethoxycarbonylamino)butanoic acid. Its molecular formula is C13H15NO6. It is an aspartic acid derivative used as a building block in peptide synthesis. It has no approved therapeutic indications.
|
| Molecular Formula |
C13H15NO6
|
|---|---|
| Molecular Weight |
281.2613
|
| Exact Mass |
281.089
|
| CAS # |
4668-42-2
|
| PubChem CID |
7021783
|
| Appearance |
White to off-white powder
|
| Density |
1.3±0.1 g/cm3
|
| Boiling Point |
498.9±45.0 °C at 760 mmHg
|
| Melting Point |
89.3ºC (dec.)
|
| Flash Point |
255.6±28.7 °C
|
| Vapour Pressure |
0.0±1.3 mmHg at 25°C
|
| Index of Refraction |
1.540
|
| LogP |
2.11
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
20
|
| Complexity |
351
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
COC([C@@H](NC(OCC1=CC=CC=C1)=O)CC(O)=O)=O
|
| InChi Key |
MFFFBNAPQRDRQW-JTQLQIEISA-N
|
| InChi Code |
InChI=1S/C13H15NO6/c1-19-12(17)10(7-11(15)16)14-13(18)20-8-9-5-3-2-4-6-9/h2-6,10H,7-8H2,1H3,(H,14,18)(H,15,16)/t10-/m0/s1
|
| Chemical Name |
(3S)-4-methoxy-4-oxo-3-(phenylmethoxycarbonylamino)butanoic acid
|
| Synonyms |
Z-Asp-OMe
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.5554 mL | 17.7771 mL | 35.5543 mL | |
| 5 mM | 0.7111 mL | 3.5554 mL | 7.1109 mL | |
| 10 mM | 0.3555 mL | 1.7777 mL | 3.5554 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
